Helping you understand psychedelic research

Papers | Trials | Reports | Events

Leverage our databases to stay up-to-date with
the transition from research trials to practice

Changed Substance Use After Psychedelic Experiences Among Individuals in Canada
This cross-sectional online survey (n=1639) investigated self-reported changes in substance use associated with past or current psychedelic use. Results indicate that 43% reported decreasing or ceasing alcohol, cocaine, or antidepressant use. Conversely, the highest rates of increased use were reported for cannabis and tobacco products (10%). Key reasons for substance use reductions included increased self-connection, less anxiety or depression, and connection with nature and others. Factors leading to reduction in any substance use included the motivation to treat a medical condition, the number of psychedelics used, younger age, and using both microdoses and macrodoses.
Category: Papers
Published: 2023-06-01
Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants
This double-blind, placebo-controlled crossover trial (n=27) investigated different intravenous DMT administration regimens, including placebo, low and high infusion (0.6-1mg/min), and bolus doses (15-25mg) combined with low and high infusion. The study found that bolus doses rapidly induced intense psychedelic effects, with infusions causing slowly increasing, dose-dependent effects.
Category: Papers
Published: 2023-06-01
Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
This randomized, double-blind, placebo-controlled, cross-over study (n=32) investigated the effects of mescaline, LSD, and psilocybin at psychoactive-equivalent doses. The acute subjective effects of these substances were comparable, and all had moderate autonomic effects with minor differences in diastolic blood pressure and heart rate. Mescaline induced slightly more subacute adverse effects, and differences were found in the duration of action, with mescaline lasting the longest.
Category: Papers
Published: 2023-05-31
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial
This double-blind, placebo-controlled study (n=30) explores oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus), using MDMA as a biochemical and psychoactive provocation test. The participants included patients with vasopressin deficiency and healthy controls, who were given either MDMA or placebo in a randomized order over two sessions.
Category: Papers
Published: 2023-05-30
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth
This retrospective analysis (n=52) investigates the efficacy of ketamine (35-52mg/70kg; 4x) for treating treatment-resistant depression (TRD) in transitional age youth (TAY; age 18-25), comparing them with matched adults. The study finds significant reductions in depression, anxiety, and suicidal ideation in the TAY group, with effect sizes indicative of clinically meaningful improvements. The benefits and safety outcomes in the TAY group were comparable to the GA group, suggesting ketamine can be equally effective and well-tolerated in younger patients with TRD.
Category: Papers
Published: 2023-05-30
Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches
This pilot study (n=10) examines the efficacy of ketamine-assisted psychotherapy (KAP) in individuals diagnosed with both chronic pain and major depressive disorder (MDD). The participants were divided equally into two groups: one receiving high-dose intramuscular ketamine before therapy (psychedelic approach) and the other receiving low-dose sublingual ketamine during therapy (psycholytic approach). No statistically significant difference between the groups was found, but both improved.
Category: Papers
Published: 2023-05-30
Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
This survey (n=17) investigates cardiovascular adverse events (AEs) associated with MDMA-assisted therapy sessions, utilizing the FDA Adverse Event Reporting System. The study finds that all cases of cardiovascular AEs involved using additional substances alongside MDMA, all of which had been previously associated with cardiovascular AEs. MDMA was not marked as the primary suspect in any of the reports.
Category: Papers
Published: 2023-05-30
Managing Medical Risk In Patients Seeking Psilocybin Therapy
Managing Medical Risk In Patients Seeking Psilocybin Therapy is an online, self-paced course offering healthcare providers comprehensive insights into psilocybin therapy. Gain vital knowledge about psilocybin, its legality, research indications, and learn to manage medical risks in this rapidly evolving field of psychedelic medicine.
Category: Courses
Published: 2023-05-30
Pós-GradUação em Psicotereapia Assistida por Psicodélicos
Explore the first MEC-approved Postgraduate Course in Psychedelic-Assisted Psychotherapy in Brazil, designed for psychologists and psychiatrists. Learn cutting-edge therapeutic techniques, gain practical experience, and contribute to pioneering research.
Category: Courses
Published: 2023-05-30
Time-resolved network control analysis links reduced control energy under DMT with the serotonin 2a receptor, signal diversity, and subjective experience
This re-analysis (n=14) applies a receptor-informed network control theory framework to investigate the effects of DMT on the brain's control energy landscape. It reveals that DMT, like LSD and psilocybin, reduces global control energy, with these trajectories correlating with EEG signal diversity and subjective intensity ratings. Furthermore, the regional effects of DMT correlate with serotonin 2a receptor density, demonstrating a potential proof-of-concept for predicting pharmacological intervention effects on brain dynamics using control models.
Category: Papers
Published: 2023-05-23

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Find the right paper, company, person in over 3.000 entries & 100.000 parameters

Explore Databases

Well-Researched Reports

Survey the psychedelic landscape with reports on 18 topics, 14 compounds & 20 countries

Explore Reports

Timely Insights

Stay in the loop with the latest articles on research & implementation

Explore Insights

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

A weekly email, sent on Tuesday (paid) or Thursday (free), packed with the latest
psychedelic research, news & actionable insights

Stay up-to-date with psychedelic research

  • Weekly psychedelic research newsletter
  • Unlimited browsing on Blossom
  • 2000+ Research Papers (short summaries)
Join

€29 p/month | Blossom Pro

  • Unlimited access for one account
  • Receive The Bloom two days earlier
  • Full reports & extended research summaries
  • Personal profile priority updates
  • chatBlossom (our chat interface, in development)
Learn More

Cancel anytime

€69 p/m | Blossom Business

  • Unlimited access for up to ten accounts
  • All Pro membership benefits, Plus:
  • Company profile priority updates
  • Connect via API (show/remix our data on your platform)
Learn More

Cancel anytime

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Bloom newsletter and databases are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report

Reports

All our reports are available for free, with extra content for paying members

Clinical Topics

Addiction

Alcohol Use Disorder

Opioid Use Disorder

Smoking

Anxiety

Autism

Borderline

Depression

Bipolar

Postpartum

Suicidality

Treatment-Resistant Depression

Eating Disorders

Pain

Fibromyalgia

Headache Disorders

PTSD

Immunity

Neurocognitive Disorders

Obsessive-Compulsive Disorder

Schizophrenia

Traumatic Brain Injury

More Topics

Chemistry

Creativity

Economics

Equity and Ethics

Public Health, Prevention & Behaviour Change

Healthy Subjects

Microdosing

Music

Neuroscience

Palliative Care

Personality

Population Surveys

Relationships

Safety

Technology

Psychedelic Compounds

2C-X

5-MeO-DMT

Ayahuasca

DMT

Ibogaine

Ketamine

Kratom

LSD

MDMA

Mescaline

Nitrous Oxide

Placebo

Psilocybin

Salvia Divinorum

Countries

United States

United Kingdom

Canada

Australia

Europe

Switzerland

Netherlands

Belgium

Germany

France

Spain

Portugal

Italy

Denmark

Norway

“It is wonderful to receive the Bloom newsletter summarising the latest psychedelics research. With so many exciting studies in the psychedelic space, it can be hard to keep up!”

Anne Katrin Schlag

Acting CEO & Head of Research, Drug Science

“Blossom is my go-to resource for the latest in research. It’s the only site to which I refer people who want a comprehensive search for and thoroughgoing analysis of psychedelic studies and papers.”

Rick Strassman

Clinical Associate Professor of Psychiatry, University of New Mexico School of Medicine
Author, DMT: The Spirit Molecule